|GeorgeRic||Дата: Понедельник, 25 Август 2014, 09:02:01 | Сообщение # 1|
|Patients treated with both dosing regimens of ixekizumab had significantly greater levels of fell space compared to placebo and to etanercept at the 12-week endpoint. Epidermis licence was quantified close level primary endpoints looking for psoriasis studies: the Psoriasis Parade-ground and Inhumanity Directory (PASI) and the Static Physician Global Assessment (sPGA). |
On patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI accompaniment (PASI 75) at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or distinct bark, at week 12. An eye to comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100.
Statistically valued improvements in husk clearance measures exchange for patients treated with ixekizumab were observed as cock's-crow as the oldest week when compared to either placebo or etanercept, and continued in every way week 12. In the UNCOVER-1 ruminate on, high levels of effect were maintained through 60 weeks of treatment.
<a href=http://woodlandindianartcenter.org/buy/Aralen.php> Order Aralen USA gbd</a>
[url=http://alluredecor.ca/product/Adalat.php] Price Adalat US bg[/url]